Results 181 to 190 of about 66,330 (250)

New insights into transcription elongation control of HIV-1 latency and rebound. [PDF]

Trends Immunol, 2023
Mbonye U, Kizito F, Karn J.
europepmc   +1 more source

Muddy Water Pneumonitis: An Emerging Occupational Lung Disease in Professional Divers

Respirology Case Reports, Volume 14, Issue 8, August 2026.
Chronic exposure to sediment‐rich river water in a professional diver led to progressive necrotizing lung injury mimicking tuberculosis. Bronchoalveolar lavage revealed Acinetobacter, highlighting a rare occupational cause of cavitary pneumonitis.
Sadia Sultana Resma, Dewan Azmal Hussain, Rashedul Hasan Ripon, Fazle Rabbi   +3 more
wiley   +1 more source

Ethnopharmacological exploration and isolation of HIV-1 latency-reversing agents from Sudanese medicinal plants. [PDF]

Front Pharmacol
Elamin KM, Kishimoto N, Kawahara T, Idris Elbashir SM, Yasutake T, Wada M, Hitora Y, Kordofani M, Osman W, Elbashir MI, Misumi S.   +10 more
europepmc   +1 more source

Upstream Stimulatory Factors Regulate HIV-1 Latency and Are Required for Robust T Cell Activation. [PDF]

Viruses, 2023
Horvath RM, Sadowski I.
europepmc   +1 more source

Infection control in the brain and the eye

Acta Ophthalmologica, Volume 104, Issue 5, Page e478-e490, August 2026.
Abstract The Central Nervous System (CNS), comprising the brain and the eye, is considered to have a ‘privileged’ mechanism for dealing with immunological challenge (immune privilege, IP). CNS IP has been revealed through experiments using foreign protein antigens and cell and tissue alloantigens (grafts), but evidence for a role for IP in modulating ...
John V. Forrester, Paul G. McMenamin, Samantha J. Dando   +2 more
wiley   +1 more source

Impact of chromatin on HIV-1 latency: a multi-dimensional perspective. [PDF]

Epigenetics Chromatin
Jones JE, Gunderson CE, Wigdahl B, Nonnemacher MR.   +3 more
europepmc   +1 more source

Epigenetic silencing by the SMC5/6 complex mediates HIV-1 latency. [PDF]

Nat Microbiol, 2022
Irwan ID, Bogerd HP, Cullen BR.
europepmc   +1 more source

Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 4, Page 458-470, August 2026.
RESTORE is a prospective, double‐blind, placebo‐controlled, crossover trial evaluating Lemborexant in cirrhosis at Cipto Mangunkusumo National Referral Hospital. Both 5 and 10 mg doses reduced PSQI by week 2, with sustained benefits post‐crossover. The 5 mg group improved Stroop Test performance, whereas the 10 mg group had prolonged reaction time ...
Rino Alvani Gani, Pitt Akbar, Irsan Hasan, Andri Sanityoso Sulaiman, Cosmas Rinaldi Adithya Lesmana, Juferdy Kurniawan, Sarah Melissa Panjaitan, Valerie Josephine Dirjayanto   +7 more
wiley   +1 more source

A targeted CRISPR screen identifies ETS1 as a regulator of HIV-1 latency. [PDF]

PLoS Pathog
Ashokkumar M, Hafer TL, Felton A, Archin NM, Margolis DM, Emerman M, Browne EP.   +6 more
europepmc   +1 more source

Chemokines in Alzheimer's Disease: Early Defence, Late Damage and the Impact of Sex and Infection

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.
ABSTRACT Chemokines constitute a versatile signalling network maintaining homeostasis and glia–neuron communication in the healthy brain but become progressively dysregulated during aging and Alzheimer's disease (AD). This review examines how chemokine systems transition from tightly regulated homeostatic signals to drivers of chronic neuroinflammation
Blanca I. Aldana, Kristine Freude
wiley   +1 more source